Overview
Radiprodil has been used in trials studying the treatment of Infantile Spasms (IS) and Diabetic Peripheral Neuropathic Pain.
Indication
No indication information available.
Associated Conditions
No associated conditions information available.
Research Report
Radiprodil (DB12260): A Comprehensive Report on its Pharmacology, Clinical Development, and Therapeutic Potential
1. Introduction to Radiprodil
1.1. Overview
Radiprodil is an investigational small molecule drug that has been evaluated for a range of neurological conditions. Its development journey has seen a strategic evolution, moving from broader applications to a more focused approach targeting rare, severe neurodevelopmental disorders where its specific mechanism of action is most relevant.[1] Initially explored for conditions such as Infantile Spasms (IS) and Diabetic Peripheral Neuropathic Pain (DPNP), radiprodil is currently under active clinical development primarily for GRIN-related Neurodevelopmental Disorders (GRIN-NDD), Tuberous Sclerosis Complex (TSC), and Focal Cortical Dysplasia (FCD) Type II. This shift underscores a trend towards precision medicine, leveraging a deeper understanding of the drug's molecular interactions and the pathophysiology of specific diseases.
The development pathway of radiprodil highlights the complexities and iterative nature of pharmaceutical research. Early setbacks in demonstrating efficacy for more common conditions have not led to its abandonment but rather to a refined strategy. This redirection is based on emerging clinical data and a clearer understanding of how radiprodil's unique pharmacological profile can address the underlying mechanisms of specific, often genetically defined, patient populations.
1.2. Key Identifiers and Properties
Radiprodil is characterized by several key identifiers and properties that define its nature and therapeutic focus:
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
---|---|---|---|---|---|
2024/04/30 | Phase 1 | Recruiting | |||
2023/04/19 | Phase 1 | Active, not recruiting | |||
2016/07/12 | Phase 2 | Terminated | UCB Biopharma S.P.R.L. | ||
2016/01/06 | Phase 1 | Completed | UCB Biopharma S.P.R.L. | ||
2009/02/06 | Phase 2 | Completed | Forest Laboratories |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
---|---|---|---|---|---|
No FDA approvals found for this drug. |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
---|---|---|---|
No EMA approvals found for this drug. |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No HSA approvals found for this drug. |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
---|---|---|---|---|---|
No NMPA approvals found for this drug. |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
---|---|---|---|---|---|
No PPB approvals found for this drug. |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
---|---|---|---|---|---|
No TGA approvals found for this drug. |
Help Us Improve
Your feedback helps us provide better drug information and insights.